On Friday, Shares of Amarin Corporation plc (ADR)(NASDAQ:AMRN), subtract -1.00% and closed at $2.96 in the last trading session. The last trading range of the stock ranges between $2.94 and $3.02. Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The companys lead product includes Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels.
Boeing Co (NYSE:BA), jumped 0.09% and closed at $133.50 in the last trading session. The last trading range of the stock ranges between $133.48 and $135.25. The company’s Market capitalization is $83.36 Billion with the total outstanding Shares of 623.83 million. The Boeing (BA) board of directors has elected Robert A. Bradway as a new member.
Bradway, 53, is chairman and CEO of Amgen, one of the world’s leading biotechnology companies.
Bradway joined Amgen in 2006 and has served the company in senior finance and operations strategy roles, counting chief financial officer and chief operating officer. He was elected CEO in 2012 and chairman in 2013. He joined Amgen from Morgan Stanley where he had responsibility for the firm’s banking department and corporate finance activities in Europe.
“Bob brings to the Boeing board a global perspective from a company making long-term investments in an advanced high-technology and innovation-focused industry,” said Boeing Chairman, President and CEO Dennis Muilenburg. “His accomplishments in business, operations and finance will serve Boeing well as he applies his broad-based experience to aerospace.”
Halozyme Therapeutics, Inc. (NASDAQ:HALO), lost -4.28% and closed at $10.06 in the last trading session. The last trading range of the stock ranges between $9.96 and $10.72. The company’s Market capitalization is $1.25 Billion with the total outstanding Shares of 129.41 million. During the 52-week trading session the minimum price at which share price traded, registered at $6.96 and reached to max level of $18.65. Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the third quarter 2016 on Mon., Nov. 7, 2016 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date post-market, Halozyme will release financial results for the third quarter 2016.